On November 20, 2023, HC Wainwright & Co. made the decision to maintain its Buy rating for SpringWorks Therapeutics (NASDAQ: SWTX) while adjusting its price target to $52.00 from $58.00. Interestingly, shares of SpringWorks Therapeutics have seen a 3.91% increase in the last 24 hours, currently trading at $22.30 per share. If the price target of $52.00 is reached, it would signify an impressive 133.18% surge in the stock price.
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company that primarily focuses on the development and commercialization of medications for rare diseases and cancer patients who are often overlooked. Their portfolio consists of targeted oncology product candidates, which are small molecules designed to address specific genetic mutations. The company is actively progressing with clinical trials that have the potential to gain regulatory approval in rare tumor types, as well as other programs that target genetically defined cancers.
Analyst ratings, such as the Buy rating upheld by HC Wainwright & Co., offer valuable insights from experts in the banking and financial industry. These analysts typically evaluate stocks on a quarterly basis, providing recommendations and even forecasting metrics such as growth estimates, earnings, and revenue. This guidance aids investors in making informed decisions about their stock portfolios.
SpringWorks Therapeutics, Inc.
Updated on: 22/11/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
4:00 AM (UTC)
Date:22 November, 2023
|Analyst / firm||Rating|
SWTX Stock Analysis: Volatile Trading Day and Mixed Earnings Growth
SWTX stock, belonging to the Health Technology sector and the Pharmaceuticals: Major industry, had an eventful trading day on November 20, 2023. Let’s take a closer look at its performance based on the information provided.
The stock opened at $21.51, slightly higher than the previous day’s closing price of $21.46. Throughout the day, the stock price fluctuated within a range of $21.49 to $22.80. This indicates that there was some volatility in the stock’s price during the trading session.
The trading volume for the day was 29,070 shares. This is significantly lower than the average volume of 590,443 shares over the past three months. The lower trading volume suggests that there was less investor interest in the stock on this particular day.
SWTX has a market capitalization of $1.3 billion. This represents the total value of all its outstanding shares.
Looking at the earnings growth, SWTX experienced a decline of 45.17% in the previous year. However, there was a positive growth of 5.10% in earnings this year. Furthermore, the company is expected to have a robust earnings growth of 19.70% over the next five years. These figures indicate that SWTX has been working towards improving its financial performance.
It is worth mentioning that SWTX’s revenue growth for the last year is not available.
The P/E ratio and Price/Sales ratio for SWTX are not provided.
The Price/Book ratio for SWTX is 2.35. This ratio compares the company’s market value to its book value, indicating whether the stock is overvalued or undervalued. A Price/Book ratio of 2.35 suggests that the stock is trading at a moderate premium to its book value.
Unfortunately, no competitor data is available for SWTX.
The next reporting date for SWTX is scheduled for February 22, 2024.
The EPS forecast for the current quarter is -$1.09.
In terms of its financials, SWTX reported annual revenue of $0.00 in the last year. Additionally, the company incurred an annual loss of -$277.4 million.
Unfortunately, there is no information available regarding SWTX’s net profit margin.
In conclusion, SWTX had an eventful trading day on November 20, 2023, with some volatility in its stock price. The company has shown mixed earnings growth in the past, but there are positive signs of improvement in its financial performance. However, the absence of revenue growth data and competitor information makes it challenging to assess SWTX’s overall position within the industry. Investors should closely monitor the company’s upcoming financial reports to gain a better understanding of its performance.
SpringWorks Therapeutics Inc (SWTX) Stock Analysis: Potential 102.43% Increase and Consensus to Buy
On November 20, 2023, SpringWorks Therapeutics Inc (SWTX) had a last price of $22.23. According to data from CNN Money, the five analysts offering 12-month price forecasts for SWTX had a median target of $45.00, with a high estimate of $58.00 and a low estimate of $41.00. This median estimate represents a potential increase of 102.43% from the last price.
The current consensus among six polled investment analysts is to buy stock in SpringWorks Therapeutics Inc. This rating has remained steady since November, when it was unchanged from a buy rating.
SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative medicines for patients with severe rare diseases and cancer. The company’s mission is to improve the lives of patients and their families by bringing transformative therapies to market.
Investors should conduct thorough research and analysis before making any investment decisions. It is crucial to consider the analysts’ forecasts, but also to evaluate the company’s fundamentals and industry trends. Additionally, investors should be aware that stock prices can be volatile and subject to market fluctuations.
SpringWorks Therapeutics Inc is scheduled to report its earnings for the current quarter on February 22. This information will provide further insights into the company’s financial performance and may impact the stock’s future performance.
In conclusion, SWTX stock had a last price of $22.23 on November 20, 2023. Analysts have a median target of $45.00 for the stock, indicating a potential increase of 102.43% from the last price. The consensus among investment analysts is to buy stock in SpringWorks Therapeutics Inc. However, investors should conduct thorough research and analysis before making any investment decisions, taking into account the company’s financial performance, pipeline, and market conditions.